Management of acute ischemic stroke
Department of Pharmacology, Maharishi Arvind Institute of Pharmacy, Jaipur, Rajasthan, India.
Review
World Journal of Biology Pharmacy and Health Sciences, 2022, 12(03), 210-215.
Article DOI: 10.30574/wjbphs.2022.12.3.0231
Publication history:
Received on 26 October 2022; revised on 12 December 2022; accepted on 14 December 2022
Abstract:
Stroke is a major cause of mortality and morbidity, and thrombolysis has served as a catalyst for major changes in the management of acute ischaemic stroke. Intravenous alteplase (recombinant tissue plasminogen activator) is the only approved thrombolytic agent at present indicated for acute ischaemic stroke. Recombinant tissue plasminogen activator (rt-PA) therapy is effective in reducing early and long-term neurologic disabilities if it is started quickly. This article summarizes the recent advances in thrombolysis for acute ischaemic stroke.
Keywords:
Cerebral edema; Penumbra; Secondary neuronal injury; Stroke; rt-PA
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0